Breathe Well Live Well
 RTT News |
GlaxoSmithKline Boosts Stake In Theravance To 27%
NASDAQ The move is said to be on the potential success of asthma drug Relovair, which is believed to be the successor of Seretide/Advair that logged sales of roughly $8.1 billion in 2011. Relovair is developed by Theravance and GlaxoSmithKline and is a … GlaxoSmithKline to Increase Its Ownership in Theravance GlaxoSmithKline invests $213M in Theravance Inc. Glaxo Lifts Theravance Stake |
View full post on asthma – Google News
|
Market Report: GlaxoSmithKline stays healthy on asthma news
The Independent There have been concerns the group's major asthma product could be knocked by generic versions being produced, but Goldman Sachs said it now appeared likely a rival drug by Sandoz would be delayed. As a result, scribblers from the broker said they … |
View full post on asthma – Google News
|
GlaxoSmithKline Grows Theravance Stake: Investing in the Pipeline
Seeking Alpha Chief among the products of their collaboration to date is Relovair, heir to the throne of Advair, GSK's best-selling medicine for asthma attacks and COPD. … |
View full post on asthma – Google News
 Minyanville.com |
GlaxoSmithKline Ties Up Loose Ends With Relovair
Minyanville.com The FDA recently made more stringent requirements for drugs that contain long-acting beta agonists for the treatment of asthma due to safety concerns. … Glaxo, Theravance report Relovair safety data GlaxoSmithKline, Theravance Combined Drug for COPD Shows Postitive Results GSK and Theravance announce combination ICS/LABA Phase II results in the … |
View full post on asthma – Google News
 Proactive Investors USA & Canada |
GlaxoSmithKline, Theravance Combined Drug for COPD Shows Postitive Results
FOXBusiness … Wednesday that their combined treatment for patients with chronic obstructive pulmonary disorder and asthma posted strong results in a clinical study. … Glaxo, Theravance report Relovair safety data GSK and Theravance announce combination ICS/LABA Phase II results in the … GlaxoSmithKline and Theravance announce positive phase II results for Relovair … |
View full post on asthma – Google News
 Stockopedia |
CORRECT: Vectura Licenses Patents To GlaxoSmithKline
Wall Street Journal VX) generics unit Sandoz handed back the US rights to VR315, a generic version of an asthma drug, to Vectura. Analysts said it signaled Sandoz wasn't sure … INTERVIEW: Vectura Patents For GSK's 573719 And 642444 Vectura and GlaxoSmithKline sign agreement over asthma patents Vectura boosted by deal with GSK worth over $30 million upfront plus royalties … |
View full post on asthma – Google News